Community-Based Seroprevelance of SARS-CoV-2 in Saudi Arabia.
| Autor: | Alassaf L; Population Health Management, Center for National Health Insurance, Riyadh, SAU., Almudarra S; Gulf Center for Disease Prevention and Control, Gulf Health Council, Riyadh, SAU., Almudaiheem A; Public Health Intelligence, Public Health Authority, Riyadh, SAU., Almutlaq H; Public Health intelligence, Public Health Authority, Riyadh, SAU., Alqunaibet A; Public Health Intelligence, Public Health Authority, Riyadh, SAU., Alseraihi H; Infectious Disease Consultant, Ministry of Health, Riyadh, SAU., Alaswad R; Public Health Intelligence, Public Health Authority, Riyadh, SAU., Khoja AT; Public Health and Preventive Medicine, Imam Mohammad Ibn Saud Islamic University, Riyadh, SAU., AlAbdulkareem K; Primary Health Care, Ministry of Health, Riyadh, SAU., AlSaif F; Department of Surgery. College of Medicine, King Saud University, Riyadh, SAU., Abu Saris R; Department of Epidemiology and Biostatistics, College of Public Health and Health Informatics, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, SAU. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2022 Dec 11; Vol. 14 (12), pp. e32419. Date of Electronic Publication: 2022 Dec 11 (Print Publication: 2022). |
| DOI: | 10.7759/cureus.32419 |
| Abstrakt: | Introduction The new coronavirus disease 2019 (COVID-19) is a major global concern. Due to the number of asymptomatic cases that go untested, the actual proportion of those who have been infected is likely to be higher than the reported prevalence. Thus, investigating the exact proportion of those who developed antibodies against the virus through serological surveys is crucial to identify the immune status of the population and direct public health decisions accordingly. Objectives The aim of this study is to estimate the seroprevalence of SARS-CoV-2 in the community and to describe the epidemiological characteristics of the discovered cases. Methods Between July and October 2020, a cross-sectional sero-survey was conducted including a total of 15,873 serum samples collected from seven regions within the kingdom. Using a multistage convenient sampling, people were invited to participate in an interviewer-administrated questionnaire. Afterward, blood samples were collected and seroprevalence was determined using the SARS-CoV-2 virus IgG/IgM antibody detection kits (ELISA). A p-value of <0.05 and 95% CI were used to report the significance. Results The overall seroprevalence of SARS-CoV-2 in the sample was 17.0%, and Makkah region constituted the highest number of reactive cases (33.3%). There was a significant association between all comorbidities and having symptoms except for diabetes. In addition, age, education, nationality, and region were all significant predeterminants of sero-result. Also, contact with a confirmed or suspected case increased the risk of being seropositive by nearly 1.5 times. Conclusion This study estimated the national seroprevalence of SARS-CoV-2 in Saudi Arabia to be 17%. At the time of this study, most of the population did not have the SARS-CoV-2 specific antibodies. This suggests that the population is still below the threshold of herd immunity and emphasizes the importance of mass vaccination programs and abiding by recommended prevention precautions. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2022, Alassaf et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|